Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday broker round-up UPDATE

Wed, 22nd May 2013 09:37

Afferro Mining: Panmure Gordon reduces target price from 279p to 100p, while keeping its buy recommendation.Amara Mining: Westhouse Securities cuts target price from 110p to 90p retaining a buy recommendation.Amlin: Westhouse Securities moves target price from 455p to 470p and upgrades to add.ARM Holdings: Berenberg increases target price from 1150p to 1350p and maintains a buy recommendation.Beazley: Westhouse Securities shifts target price from 235p to 245p, while downgrading to neutral.Britvic: Investec places both its target price (prev.: 447p) and its buy recommendation under review.Burberry: JP Morgan increases target price from 1320p to 1400p and keeps a neutral rating. Deutsche Bank raises target price from 1400p to 1530p, while its hold recommendation remains unchanged. Credit Suisse ups target price from 1550p to 1600p and maintains an outperform rating.Capita Group: Investec ups target price from 865p to 1000p upgrading from sell to hold. HSBC Holdings increases target price from 775p to 1050p upgrading to neutral.Carnival: Morgan Stanley reduces target price from 2400p to 2200p, while reiterating an equal-weight rating. Deutsche Bank cuts target price from 2780p to 2640p staying with its buy recommendation. Exane takes target price from 2400p to 2200p and retains a neutral rating. HSBC Holdings reduces target price from 2900p to 2500p and downgrades to neutral.Catlin Group: Westhouse Securities takes target price from 530p to 590p upgrading to add.Darty: Citi shifts target price from 39p to 47p, but still recommends selling. Exane moves target price from 50p to 65p and maintains a neutral rating. Societe Generale takes target price from 51p to 68p, while downgrading to hold.Faroe Petroleum: Jefferies lowers target price from 210p to 200p, while keeping its buy recommendation.First Group: Morgan Stanley cuts target price from 195p to 176p, while upgrading to equal-weight.GlaxoSmithKline: Exane raises target price from 1400p to 1500p, but keeps its underperform rating.Great Portland Estates: Investec increases target price from 515p to 630p, while reiterating an add rating.Griffin Mining: Cantor Fitzgerald ups target price from 40p to 70p and upgrades to buy.Hikma Pharmaceuticals: Credit Suisse takes target price from 820p to 1050p, while its outperform rating is kept.Hiscox: Westhouse Securities shifts target price from 530p to 540p and keeps a neutral rating.Hogg Robinson Group: Investec lowers target price from 100p to 95p, while maintaining its buy recommendation. Canaccord Genuity shifts target price from 90p to 85p and retains a buy recommendation.Homeserve: Jefferies ups target price from 210p to 240p keeping a hold recommendation.HSBC Holdings: Bank of America ups target price from 755p to 785p and reiterates a neutral rating.Imagination Technologies Group: Berenberg reduces target price from 360p to 250p and leaves its sell recommendation unchanged.Informa: Westhouse Securities downgrades from add to neutral with a target price of 525p.Innovation Group: Investec moves target price from 30p to 33p maintaining a buy recommendation. Panmure Gordon shifts target price from 38p to 39p and keeps a buy recommendation.Invensys: Exane raises target price from 350p to 380p reiterating a neutral rating.Kazakhmys: UBS reduces target price from 465p to 385p and downgrades from buy to neutral.Magnolia Petroleum: Northland Capital initiates with a target price of 4.60p and a buy recommendation.Man Group: Citi moves target price from 110p to 130p and retains a neutral rating.Marks & Spencer: Nomura increases target price from 500p to 540p maintaining a buy recommendation. Citi ups target price from 440p to 470p and stays with its neutral rating. Deutsche Bank moves target price from 450p to 465p and leaves its hold recommendation unaltered. Exane raises target price from 310p to 390p keeping an underperform rating. Societe Generale ups target price from 472p to 581p and retains a buy recommendation. HSBC Holdings takes target price from 390p to 490p and maintains a neutral rating.MITIE: Jefferies cuts target price from 300p to 285p and maintains a hold recommendation.NetDimensions: Panmure Gordon ups target price from 118p to 124p reiterating its buy recommendation.Novae Group: Westhouse Securities raises target price from 450p to 500p and retains a neutral rating.Optimal Payments: Canaccord Genuity takes target price from 200p to 220p and retains a buy recommendation.Optos: N+1 Singer reduces target price from 150p to 135p, while upgrading to hold.Paragon Group: JP Morgan moves target price from 300p to 361p maintaining an overweight rating.Petropavlovsk: Westhouse Securities lowers target price from 285p to 275p keeping its buy recommendation.PZ Cussons: Panmure Gordon increases target price from 380p to 400p and retains a hold recommendation.RPS Group: Jefferies lowers target price from 285p to 275p, while leaving its buy recommendation unchanged.Shaftesbury: Investec takes target price from 550p to 690p and retains a hold recommendation.UK Mail Group: Investec raises target price from 465p to 600p and stays with its buy recommendation.Vectura: JP Morgan shifts target price from 133p to 148p and stays with its overweight rating.
More News
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.